Denosumab
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Denosumab: Drug Repurposing Evaluation — Insufficient Data to Complete Assessment
One-Sentence Summary
Denosumab (DrugBank ID: DB06643) is included in this repurposing pipeline; however, the current Evidence Pack contains no original indication records, no TxGNN-predicted new indications, and no mechanism of action data. A standard repurposing evaluation cannot be completed at this time — the decision is Hold pending data remediation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this Evidence Pack |
| Predicted New Indication | No TxGNN predictions available |
| TxGNN Prediction Score | — |
| Evidence Level | L5 — pipeline output not yet generated |
| Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why Cannot the Evaluation Proceed?
Three critical data gaps block a complete repurposing assessment for Denosumab:
1. No TxGNN predicted indications. The predicted_indications array is empty. Without a target disease, all downstream analysis — clinical trial mapping, literature review, and mechanism plausibility scoring — cannot be performed. This is the single most important prerequisite for generating this report.
2. No mechanism of action (MOA) data. The MOA field was flagged as a High-severity gap (DG002). Understanding how Denosumab works at the molecular level is essential for evaluating whether any new indication is mechanistically plausible.
3. No safety profile. Package insert warnings and contraindications are absent (DG001, Blocking severity). Safety screening is a prerequisite before any clinical feasibility assessment can begin.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Denosumab's Evidence Pack is missing all three minimum inputs for a valid repurposing evaluation: TxGNN predictions, mechanism of action, and safety data. Proceeding without these would produce an assessment with no evidential basis.
To proceed, the following is needed:
- [Blocking] Run the TxGNN pipeline to generate predicted indications for Denosumab (DB06643)
- [Blocking] Download and parse the package insert PDF to extract warnings and contraindications
- [High] Query the DrugBank API for Denosumab's mechanism of action
- Re-submit the completed Evidence Pack for a full evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.